非小细胞肺癌组织中ERCC1mRNA表达的及其与辅助化疗和预后的关系

Analysis of ERCC1 mRNA expression to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy

目的探讨非小细胞肺癌(NSCLC)患者切除修复交叉互补基因1(ERCC1) mRNA的表达情况及其与铂类药物辅助化疗和预后的关系。方法应用逆转录-PCR(RT-PCR)实验技术,检测85例NSCLC和34例癌旁组织中ERCC1 mRNA的表达情况。回顾性分析ERCC1表达情况与患者辅助化疗后无进展生存期以及总生存期之间的关联性。结果患者ERCC1 mRNA阴性表达较阳性表达具有更长的无进展生存期(P=0.001)和总生存期(P=0.001)。多因素分析显示,ERCC1为无进展生存期(P=0.018)和总生存期(P=0.027)的独立预后指标。结论 NSCLC患者ERCC1 mRNA的检测可能作为其术后的生存预测性因素,通过此项检测可对术后接受含铂辅助化疗的患者进行个体化的指导。

Objective To discover the excision repair cross-complementing 1 （ERCC1） expression in non-small cell lung cancer （NSCLC） patients and explore the prognostic value of ERCC1 .Methods The ERCC1 mRNA expressions in NSCLC was tested from 85 tumor tissues and 34 adjacent tissue samples from patients who were after the surgery were used by semi-quantitative RT-PCR .The data of clinical features and progression-free survival （PFS） and overall survival （OS） were linked to ERCC1 expression by retrospective analysis .Results In 85 patients ,the ERCC1 negative ones had a significantly longer survival than the ERCC1 posi-tive expression ones （PFS ,P=0 .001;OS ,P=0 .001） .During the multivariate analysis ,ERCC1was found to be a significant factor in PFS and OS （P=0 .018 and P=0 .027） .Conclusion NSCLC patients who were undertaken platinum-based adjuvant chemother-apy after surgery could use the detection of ERCC1 mRNA as a determinant factor for the prognosis predicting of individualized treatment .